LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Начало・Списък с акции・Bridgebio Pharma Inc
Search

Bridgebio Pharma Inc

Затворен

СекторЗдравеопазване

65.44 -1.15

Силна покупка

Обновена цена 1.06.2026 г., 19:59 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

65.2

Максимум

67.18

Ключови измерители

By Trading Economics

Приходи

24M

-167M

Продажби

40M

195M

EPS

-0.84

Марж на печалбата

-85.626

Служители

834

EBITDA

75M

-105M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+62.24% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

163M

14B

Предишно отваряне

66.59

Предишно затваряне

65.44

Настроения в новините

By Acuity

100%

0%

320 / 344 Класиране в Healthcare

Bridgebio Pharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

DJ

Прочетени

31.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

31.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

DJ

Прочетени

31.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

DJ

Прочетени

31.05.2026 г., 22:54 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

DJ

Прочетени

29.05.2026 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

DJ

Прочетени

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

DJ

Прочетени

29.05.2026 г., 20:53 ч. UTC

Печалби

Oil Declines Lift Stocks to Fresh Records -- WSJ

DJ

Прочетени

29.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

DJ

Прочетени

29.05.2026 г., 20:33 ч. UTC

Пазарно говорене

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

DJ

Прочетени

29.05.2026 г., 20:11 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

DJ

Прочетени

29.05.2026 г., 19:47 ч. UTC

Печалби

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

DJ

Прочетени

29.05.2026 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Month With Gains -- Market Talk

DJ

Прочетени

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

DJ

Прочетени

29.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

DJ

Прочетени

29.05.2026 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

DJ

Прочетени

29.05.2026 г., 18:19 ч. UTC

Пазарно говорене

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

DJ

Прочетени

29.05.2026 г., 18:12 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

DJ

Прочетени

29.05.2026 г., 18:11 ч. UTC

Пазарно говорене

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

DJ

Прочетени

29.05.2026 г., 18:10 ч. UTC

Пазарно говорене

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

DJ

Прочетени

29.05.2026 г., 17:55 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

DJ

Прочетени

29.05.2026 г., 17:55 ч. UTC

Пазарно говорене

NEAR Protocol Nearly Doubles in May -- Market Talk

DJ

Прочетени

29.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

DJ

Прочетени

29.05.2026 г., 17:00 ч. UTC

Печалби

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

DJ

Прочетени

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

DJ

Прочетени

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

DJ

Прочетени

29.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

DJ

Прочетени

29.05.2026 г., 16:02 ч. UTC

Пазарно говорене

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

DJ

Прочетени

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Bridgebio Pharma Inc Прогноза

Ценова цел

By TipRanks

62.24% нагоре

12-месечна прогноза

Среден 107.5 USD  62.24%

Висок 157 USD

Нисък 82 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Bridgebio Pharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

16

Купи

2

Задържане

0

Продай

Според 18 анализатори, дали борсови рейтинги на Bridgebio Pharma Inc през последните 3 месеца.

Настроение

By Acuity

320 / 344 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Други акции от сектора

LLY

Eli Lilly and Co.

1,077

↓-2.36%

JNJ

Johnson and Johnson

223.52

↓-0.74%

ABBV

AbbVie Inc

212.36

↓-2.57%

UNH

UnitedHealth Group Inc

379.41

↑ +0.2%

MRK

Merck & Co Inc.

114.99

↓-3.04%
help-icon Live chat